Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
NCT ID NCT07724223
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This phase II trial is testing whether combining two targeted drugs—fruquintinib, which blocks blood vessel growth to tumors, and cetuximab-beta, which blocks a cancer growth signal—can shrink tumors in people with RAS wild-type metastatic colorectal cancer who have already tried at least two standard treatments. About 46 participants will take fruquintinib daily and receive cetuximab-beta by infusion every two weeks. The main goal is to see how many patients experience measurable tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fruquintinib plus cetuximab-beta
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced colorectal cancer who have run out of standard therapies.
- What could go wrong
- This is an early-phase trial with only 46 participants, so results may not apply broadly. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- Can a cholesterol drug help immunotherapy fight colorectal cancer?
- Adding a Blood-Vessel blocker to maintenance chemo may extend control of advanced colorectal cancer
- Experimental drug SHR-A1904 takes on Hard-to-Treat colorectal cancer